Avalyn Pharma Inc. AVLN
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -2.68%
- 1 year
- -2.68%
- Market cap
- 1.28B
- EPS (ttm)
- -3.96
- Shares out
- 44.52M
- Forward P/E
- -11.12
- YTD return
- -2.68%
- 1-year return
- -2.68%
- 50-day average
- 28.15
- 200-day average
- 29.88
- Enterprise value
- 922.28M
- Volume
- 437.29K
- Avg volume
- 352.09K
- Open
- 27.86
- Previous close
- 27.69
- Day's range
- 27.01 – 28.90
- 52-week range
- 22.24 – 40.17
- Analysts
- Strong Buy
- Price target
- 61.00 (+112.5%)
- Earnings date
- Feb 11, 2027
Key statistics
- Price / book
- 3.44
- Total cash
- 327.46M
- Total debt
- 16.93M
- Short % of float
- 5.19%
Fundamental scorecard
3 of 25 checks passed on AVLN’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth No data
- Profitability No data
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 52.00
- Target (mean)
- 61.00
- Target (high)
- 80.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate -0.72.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | -0.70 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.67333 | -0.67 | 0.00 | +0.49% |
| Aug 12, 2026 | Jun 30, 2026 | -0.77667 | -0.98 | -0.20 | -26.18% |
| Jun 3, 2026 | Mar 31, 2026 | -5.98 | -21.83 | -15.85 | -265.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Raymond James | init | — | Outperform |
| Aug 13, 2026 | Morgan Stanley | main | Overweight | Overweight |
| May 26, 2026 | Evercore ISI Group | init | — | Outperform |
| May 26, 2026 | Guggenheim | init | — | Buy |
| May 26, 2026 | Morgan Stanley | init | — | Overweight |
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avalynpharma.com
News
Your note
Sign in to keep a note on AVLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL JILL | Director | Purchase | Apr 30, 2026 | 0 |
| FMR LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 0 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 3,883,290 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 30, 2026 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 30, 2026 | 1,275,490 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.89% | 6,185,994 | 177.54M | Sep 29, 2026 |
| Novo Holdings A/S | 7.75% | 3,449,191 | 98.99M | Sep 29, 2026 |
| SR One Capital Management, LP | 7.43% | 3,308,649 | 94.96M | Sep 29, 2026 |
| Perceptive Advisors Llc | 6.01% | 2,675,296 | 76.78M | Sep 29, 2026 |
| Montanova Capital LLC | 5.62% | 2,503,109 | 71.84M | Sep 29, 2026 |
| NVP Associates, LLC | 5.10% | 2,268,404 | 65.10M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.77% | 1,231,620 | 35.35M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.41% | 627,190 | 18.00M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.20% | 534,440 | 15.34M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.05% | 466,565 | 13.39M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.93% | 415,610 | 11.93M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.89% | 396,069 | 11.37M | Jun 29, 2026 |
